Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform

Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform




Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform

WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore™ platform as viscosity-lowering agents to significantly optimize filtration efficiency of protein solutions during the biologics manufacturing process. The ‘857 patent reflects a significant addition to Comera’s current intellectual property portfolio and expands the potential commercial applications of SQore, broadening patent protections beyond use in therapeutic antibody formulations to include manufacturing process enhancement.

“We believe that the ‘857 patent will more broadly protect SQore’s use in manufacturing process optimization and has the potential of expanding SQore’s commercial value in biologic manufacturing, as we work with our strategic partners to transform the delivery of biologics to benefit patient care,” said Jeff Hackman, Chief Executive Officer and Chairman of Comera. “We have been significantly investing in the scientific development of our SQore platform, and today’s patent issuance reflects our efforts to strengthen our intellectual property position for SQore.”

Filtration of protein solutions is a key component of the antibody manufacturing process and is utilized for sterilization, removal of impurities, and concentration of the active ingredient to allow for use as an injected medicine. The filtration steps can be time consuming, costly, and inefficient, and an increase in filtration rate could improve the economics of production. Comera believes that its SQore technology, by lowering viscosity of high concentration protein solutions, allows for high-throughput filtration and a significantly more efficient manufacturing process.

“The benefits of Comera’s viscosity-reducing SQore technology goes well-beyond enabling subcutaneous drug formulations,” said Alan Herman, Ph.D., a scientific advisor to Comera and former Chief Scientific Officer of Coherus Biosciences. “High viscosity encountered during the downstream processing phase of drug manufacturing can significantly reduce efficiency, so technologies like SQore that can lower viscosity offer the potential to greatly optimize production throughput of antibody formulations.”

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.

Forward-Looking Statements

This press release contains includes “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: risks that the recently completed business combination disrupts the Company’s current plans and ability to retain its employees; the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company’s business; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Current Report on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors” and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Comera’s Current Report on Form 8-K filed with the SEC on May 25, 2022 and other documents filed by Comera from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.

Contacts

Comera Investor
John Woolford

ICR Westwicke

John.Woolford@westwicke.com

Comera Press
Karen Chase

ICR Westwicke

Karen.Chase@westwicke.com